US$ 21.58
do not combine dpp-4 inhibitor with glp-1 receptor agonist guideline Insights into the Roles of GLP-1, DPP-4, and SGLT2 at the Crossroads of Cardiovascular, Renal, and Metabolic Pathophysiology GLP 1 Receptor Agonists and
Description
Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial

They were found to have significant HbA1c, and weight reduction compared to placebo in patients with diabetes and obesity respectively

Rather, it focused on specifically determining the cardiovascular superiority of dulaglutide relative to cardiovascular endpoints

Safe and effective use of the once weekly dulaglutide singledose pen in injectionnave patients with type 2 diabetes

Cardiovasc Drugs Ther (2013) 27(2):1338
